Makers Laboratories

Makers Laboratories Current Liabilities

The Current Liabilities of Makers Laboratories (506919.BO) as of Oct 16, 2026 is 223.96 M INR. In the previous year, Current Liabilities was 138.89 M INR — a change of 61.24% (higher).

Current Liabilities

223.96 MINR

YoY

61.24%

Last updated:

Current Liabilities of Makers Laboratories is 2026 223.96 M INR. Current Liabilities of Makers Laboratories was 2025 138.89 M INR. It decreases by 61.24% higher compared to the previous year.

The Makers Laboratories Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
103.48 M INR
Jan 1, 2020
183.97 M INR
Jan 1, 2021
246.99 M INR
Jan 1, 2022
245.05 M INR
Jan 1, 2023
203.84 M INR
Jan 1, 2024
188.32 M INR
Jan 1, 2025
138.89 M INR
Jan 1, 2026
223.96 M INR
The Makers Laboratories Current Liabilities history
YEARCurrent LiabilitiesYoY
223.96 MINR+61.24%
138.89 MINR-26.25%
188.32 MINR-7.61%
203.84 MINR-16.82%
245.05 MINR-0.78%
246.99 MINR+34.26%
183.97 MINR+77.79%
103.48 MINR-51.70%
214.24 MINR+45.08%
147.67 MINR+63.20%
90.48 MINR-3.09%
93.36 MINR-26.76%
127.48 MINR-11.23%
143.60 MINR-9.80%
159.20 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Makers Laboratories Stock analysis

What does Makers Laboratories do? Makers Laboratories Ltd is a pharmaceutical company headquartered in Mumbai, India, operating within the Health Care sector. The company has a workforce of 121 employees and went public on July 13, 1993. It manufactures and markets pharmaceutical products, focusing on various therapeutic segments. The company's product portfolio includes formulation brands such as Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range), and Exylin (Amoxycillin range). Additionally, Makers Laboratories offers Inspira retail packs, covering categories like acid regulatory, anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics, anti-nauseants, anti-fungal, anti-hypertensives, and other health-related products. The Experia bulk packs division provides bulk pharmaceutical products including amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and similar items. The company's website is https://www.makerslabs.com/. Makers Laboratories Ltd is listed on the Bombay Stock Exchange under the ticker 506919.BO and holds the ISIN INE987A01010. The company operates through the pharmaceuticals segment, emphasizing general health therapeutic areas. It does not disclose specific financial figures or additional details beyond its product lines and operational structure. Makers Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Makers Laboratories stock

Current Liabilities of Makers Laboratories is 223.96 M INR in 2026.

Current Liabilities of Makers Laboratories changed from 138.89 M INR to 223.96 M INR, representing a 61.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Makers Laboratories since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Makers Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Makers Laboratories

All Key Metrics — Makers Laboratories